NCT01946165 - Abiraterone Acetate Plus LHRH Agonist and Abiraterone Acetate Plus LHRH Agonist and Enzalutamide | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

July 28, 2017

Study Completion Date

July 28, 2017

Conditions

Prostate Cancer

Interventions

DRUG

Abiraterone Acetate

1,000 mg by mouth daily for each 28 day cycle.

DRUG

Prednisone

5 mg by mouth once daily for each 28 day cycle.

DRUG

Enzalutamide

160 mg by mouth daily for each 28 day cycle.

DRUG

LHRHa

Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.

Trial Locations (1)

77030

University of Texas MD Anderson Cancer Center, Houston